Concurrent Presentation of Eczema Herpeticum and Acute Localized Exanthematous Pustulosis in a Patient With Atopic Dermatitis: A Rare Dermatological Convergence.

Eczema herpeticum (EH) is a severe and potentially life-threatening viral infection occurring in individuals with preexisting eczema or atopic dermatitis. It is primarily caused by the herpes simplex virus, presenting as painful vesicular eruptions on the skin. On the other hand, acute localized exanthematous pustulosis (ALEP) is a rare variant of acute generalized exanthematous pustulosis (AGEP), characterized by the sudden onset of localized, nonfollicular pustules on an erythematous base. It is often triggered by recent medication administration, and its clinical presentation mimics AGEP, although ALEP exhibits a confined distribution of pustules. Prompt diagnosis and identification of the offending agent are crucial for effective management. Both are distinct cutaneous manifestations that rarely occur concurrently, presenting unique diagnostic and therapeutic challenges.  We present the first documented case of coexisting ALEP and EH in a 32-year-old male with a history of atopic dermatitis. The patient was admitted with features suggestive of EH, including vesicular lesions over the face, along with a positive Methicillin-resistant Staphylococcus aureus (MRSA) swab. Treatment with ceftaroline initially initiated resulted in the development of localized pustules, indicative of ALEP. Transition to linezolid led to the complete resolution of both conditions, marking a compelling recovery. The distinctive interplay between EH, ALEP, and AGEP presents a novel challenge, emphasizing the need for nuanced clinical assessment and tailored therapeutic strategies. This case offers crucial insights into the intricate relationship between medication-induced dermatological conditions and underlying cutaneous vulnerabilities. This unprecedented case highlights the rarity and complex management nuances associated with the simultaneous occurrence of ALEP and EH. The successful resolution following medication adjustments underscores the need for flexibility and comprehensive evaluation in addressing such intricate dermatological scenarios, providing valuable insights into potential synergies between distinct cutaneous conditions.

Topical Corticosteroid-Induced Adrenal Insufficiency: A Case Report.

Topical Corticosteroids (TCS) are the most commonly prescribed medications in Dermatology practice. They are considered safe and effective if used at the appropriate location and for the appropriate duration. Local side effects due to TCS are not uncommon. However, systemic side effects are rare. Herein, we present a patient who developed adrenal insufficiency secondary to the use of TCS.

Quality of life assessment among patients suffering from different dermatological diseases.

OBJECTIVES: To assess the quality of life (QoL) of patients with different dermatological diseases. Multiple international studies have evaluated the QoL among patients with different dermatological diseases; however, few studies of this kind have been conducted in Saudi Arabia. METHODS: This quantitative, observational, cross-sectional study was carried out in the dermatology outpatient clinics of King Saud University Medical City, Riyadh, Saudi Arabia, from September 2019 until February 2020. Data was collected using the validated Arabic version of the Dermatology of Life Quality Index (DLQI). RESULTS: A total of 391 patients ≥18 years participated in the study. The mean age of participants was 33 years (18-75 years). Most participants in this study reported that their dermatological disease had a small or no effect on their QoL (62.5%). The majority of patients who had acne vulgaris (79.7%), vitiligo (79.3%), hair disorders (76.9%), or rosacea (71.5%) reported a small to no effects on their QoL. However, diseases that reflected the largest percentages of a large to extremely large effect on QoL were urticaria (37.1%), eczema (26.6%), and psoriasis (24%). A total of 42.9% of the participants suffered from lichen planus and 66.7% of participants suffered from cutaneous neoplasms reported a moderate effect on their QoL. CONCLUSION: Understanding the impact of different dermatological diseases on QoL can help dermatologists to improve thier patients' QoL. Therefore, we recommend that further studies on this topic be conducted in multiple health centers.